MetaCap

Kamada Ltd. (KMDA)

NASDAQ: KMDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.74-0.09 (-1.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KMDA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$446.85M
Dividend yield
7.24% ($0.56)
Ex-dividend date
Nov 19, 2026
52-week range
6.63 – 9.35
Day range
7.72 – 7.97
Volume / Avg
84.30K / 121.87K
Beta
—

52-week range

$6.63$9.35

KMDA stock today

Kamada (KMDA) closed at $7.74 on Nov 20, down 1.15% (-$0.09), versus the S&P 500's 3.70% decline. Shares are 17.2% below their 52-week high of $9.35, set on Feb 25, 2026 and 16.7% above the 52-week low of $6.63, in the middle of the past year's range. KMDA is up 9.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.7%.

Kamada trades at 20.4x its trailing twelve-month earnings per share of $0.38. Its forward P/E of 13.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Kamada pays an annual dividend of $0.56 per share, a 7.24% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Kamada

Company profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Amir London
Headquarters
Rehovot
Employees
462
IPO year
2013
Website
kamada.com

Financial highlights

Full financials

In fiscal 2025, Kamada generated $180.5 million in revenue, up 12.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $20.2 million (+39.7% year over year), for a net margin of 11.2% versus a median of 5.8% in the prior 5 years. Gross margin was 42.3% (down from 43.5%) and operating margin 14.5%.

Kamada annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$180.46M$160.95M$142.52M$129.34M$103.64M
Growth+12.12%+12.93%+10.19%+24.79%-22.22%
Net income$20.20M$14.46M$8.28M$-2.32M$-2.23M
EPS (diluted)$0.35$0.25$0.15$-0.05$-0.05

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$13.75+77.65%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$0.09 vs $0.13
Surprise
-30.77%

Dividends

Dividend history
Annual dividend
$0.56
Last payment
$0.14
Ex-dividend date
Nov 19, 2026
Pay date
Dec 9, 2026

KMDA news

All KMDA news

Kamada peers

Health Care sector
KMDA peer companies
CompanyPrice% ChgMarket capCompare
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs KMDA
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs KMDA
NGNENeurogene Inc.22.15-3.40%$458.53Mvs KMDA
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs KMDA
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs KMDA
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs KMDA
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs KMDA
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs KMDA

Indexes, lists and sector

Kamada stock FAQ

What is Kamada's stock price today?

KMDA last traded at $7.74 as of Nov 20, 4:00 PM EST, down 1.15% on the day. Prices are delayed at least 15 minutes.

Does Kamada pay a dividend?

Yes. Kamada pays $0.56 per share annually, a 7.24% yield. The most recent dividend of $0.14 had an ex-dividend date of Nov 19, 2026.

What is KMDA's P/E ratio?

KMDA trades at a trailing P/E ratio of 20.37 and a forward P/E of 13.34.

Who is Kamada's CEO?

Mr. Amir London is the chief executive officer of Kamada Ltd., which has about 462 employees.

What is the KMDA 52-week high?

The 52-week high for KMDA is $9.35 and the 52-week low is $6.63. The stock is currently 17.2% below its high.

Compare KMDA